About

Our focus is on the food and beverage, nutritional supplements, cosmetics, medical devices, and pharmaceutical industries. We provide complete legal services for the lifecycle of products aimed at improving the population’s health and wellness.

Amin Wasserman Gurnani has gained a strong reputation for its work at the cutting edge of food, drug (FDA), advertising (FTC/National Advertising Division/Direct Selling Self-Regulatory Council), and intellectual property (IP) laws, responding nimbly to rapid changes in the regulatory climate and marketplace. We work with some of the most innovative products in this sphere, such as raw juices, allergy-free foods, botanical drugs, cosmeceuticals, and hemp products. We counsel on regulatory compliance and risk analysis, product development, and trademark and patent protection.

In addition to guiding our clients through the strategic development of new products through regulatory approvals to the marketplace, we advise on all post-launch processes to ensure labeling, advertising, safety, and manufacturing compliance requirements. We counsel on recalls, consumer false advertising class actions, trademark and patent infringement disputes, FDA, FTC, and state attorney general government investigations, commercial (breach of contract) litigation, unfair competition, Proposition 65, and matters before the National Advertising Division, Direct Selling Self-Regulatory Council, and Consumer Product Safety Commission. We also provide IP and compliance due diligence assessments in mergers/acquisitions and guide companies on IP freedom-to-operate opinions.

What Our Clients Say

"Their strength is their knowledge of the regulatory and legal hurdles and for finding the best regulatory fit for a product concept. They know the health care industry leaders and the agencies that regulate them. 

This firm excels at facilitating interactions with government regulatory and industry's self regulating bodies."

– CEO of Major Pharmaceutical Company

Bob Durkin Quoted in “Makers of Dietary Supplements Push the FDA to Allow Peptides and Other New Ingredients”

Commenting on a public meeting held by the FDA to discuss its criteria for dietary supplements and whether they could be broadened to include substances that don’t come from food, vitamins, herbs or other traditional ingredients, Bob Durkin told PBS News, “The hope of the meeting is that FDA is willing to open up its […]

see all news >